Asymmetric antibodies: The antigen protective arm in a Th2-regulated immune response

Inmunologia

Volumn 21, Issue 1, 2002, Pages 29-35

  Margni, Ricardo A ^a   Gentile, M T ^a   Miranda, S ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Asymetric antibodies; Glysosylation; IgG; Th2 response

Indexed keywords

ANTIBODY; ANTIGEN; CYTOKINE;

ALLERGY; ANTIBODY PRODUCTION; CHRONICITY; COMPLEMENT FIXATION; HUMAN; IMMUNOCOMPETENCE; INFECTION; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PREGNANCY; REVIEW; TH2 CELL;

EID: 0036404816     PISSN: 02139626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Clark D, Arck P, Chaouat G. Why did your mother reject you? Am J Reprod Immunol 1999; 41: 5-22.
2. Wegmann T, Lin H, Guilbert L, Mosmann T. Bidirectional cytokine interactions in the maternal-fetal relationship: Is successfull pregnancy a Th2 phenomenon? Immunol Today 1993; 14: 353-6.
3. Hill J, Polgar K, Anderson D. T-helper I type immunity to trophoblast in women with recurrent spontaneous abortion. J Am Med Asocc 273: 1933-6.
4. Guilbert L. There is a bias against type I inflammatory cytokine expression and function in pregnancy. J Reprod Immunol 1996; 32: 105-10.
5. Marzi M, Vigano A, Trabattoni D, Vira M, Salvaggio A, Clerici E, et al. Characterisation of type 1 and 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996; 106: 127-33.
6. Haynes M, Smith J. Can Th1-like immune responses explain the immunopathology of recurrent spontaneous miscarriage? J Reprod Immunol 1997; 35: 65-71.
7. Mosmann T, Sad S. The expanding universe of T cell subsets -Th1, Th2 and more. Immunol Today 1996; 17: 138-46.
8. Clark D, Flanders K, Banwatt D, Millar-Book W, Manuel J, Stedronska-Clark J, et al. Murine pregnancy decidua produces a unique immunosuppresive molecule related to transforming growth factor 2. J Immunol 1990; 144: 3008-14.
9. Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A, Pacsa A. The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: 1. Progesterone-treated lymphocyte release a substance inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microb 1985; 10: 179-88.
10. Szekeres-Bartho J, Kinsky R, Chaouat G. The effect of a progesterone-induced immunoblocking factor on NK-mediated resorption. Am J Reprod Immunol, 1990; 24: 105-9.
11. Saito S. Cytokine network at the feto-maternal interface. J Reprod Immunol 2000; 47: 87-103.
12. Bell SC, Billington WD. Major anti-paternal autoantibody induced by murine pregnancy is non-complement fixing IgG1. Nature 1980; 288: 387-8.
13. Bell SC, Billington WD. Anti-fetal alloantibody in the pregnant female. Immunol Rev 1983; 75: 5-30.
14. Jalali GR, Arck P, Surridge S, Markert U, Chaouat G, Clark DA, et al. Immunosupressive properties of monoclonal antibodies and human polyclonal alloantibodies to the R80K protein of trophoblast. Am J Reprod Immunol 1996; 36: 129-34.
15. Agrawal S, Pandey MK, Pandey A. Prevalence of MLR blocking antibodies before and after immunotherapy. J Hematother Stem Cell Res 2000; 9: 257-62.
16. Eblen AC, Gercel-Taylor C, Shields LB, Sanfilippo JS, Nakajima ST, Taylor DD. Alterations in humoral immune responses associated with recurrent pregnancy loss. Fertil Steril 2000; 73: 305-13.
17. Malán Borel I, Gentile T, Angelucci J, Pividori J, Guala M, Binaghi R, et al. IgG asymmetric molecules with anti-paternal activity isolated from sera and placenta of pregnant human. J Reprod Immunol, 1991; 20: 129-40.
18. Margni R, Binaghi R. Non precipitating asymmetic antibodies. Annu Rev Immunol 1988; 6: 535-54.
19. Margni RA, Binaghi R. Paradoxical behaviour of asymmetric IgG antibodies. Immunological Reviews 1998; 163: 77-87.
20. Labeta M, Leoni J, Margni RA, Binaghi R. Structure of asymmetric non precipitating antibody: Presence of a carbohydrate residue in only one Fab region of the molecule. Immunology 1986; 55: 311-7.
21. Morelli L, Plotkin L, Leoni J, Fossati CA, Margni RA. Analysis of terminal oligosaccharides involved in the asymmetrical glycosylation of monoclonal antibodies. Mol Immunol 1993; 30: 695-700.
22. Ronco J, Scutto E, Leoni J, Margni R, Binaghi RA. Interaction of purified precipitating and non precipitating antibodies with hapten and with haptenated protein. Evidence of an asymmetrical antibody molecule. Immunology 1984; 52: 449-56.
23. Mathov I, Plotkin L, Squiquera L, Fossatti C, Margni R, Leoni J. N-glycanase treatment of F(ab')2 derived from asymmetric murine IgG3 mAb determines the acquisition of precipitating activity. Mol Immunol 1995; 32: 1123-30.
24. Margni RA, Perdigón G, Gentile T, Abatangelo C, Binaghi R. Immunobiological behaviour of rabbit precipitating and non-precipitating (coprecipitating) antibodies. Immunology 1980; 41: 681-6.
25. Perdigón G, Gentile T, Margni R, Abatangelo C. Human anti-tetanus toxin precipitating and coprecipitating antibodies. Immunology, 1982; 45: 183-90.
26. Leoni J, Labeta M, Margni RA. The asymmetric IgG non precipitating antibody. Localization of the oligosaccharide involved by Concanavalin A interaction. Mol Immunol 1986; 23: 1397-400.
27. Malan Borel I, Gentile T, Angelucci J, Binaghi R, Margni R. Asymmetrically glycosylated IgG isolated from non-immune human sera. Biochim Biophys Acta 1989; 990: 162-4.
28. Morelli L, Leoni J, Fossati A, Margni RA. Symmetric and asymmetric IgG antibodies are synthesized by the same cellular clone. Mol Immunol 1989; 26: 769-92.
29. Margni RA, Perdigón G, Gentile T, Abatangelo C, Dokmetjian J. IgG precipitating and coprecipitating antibodies in rabbits repeatedly injected with soluble and particulate antigens. Vet Immunol Immunopathol 1986; 13: 51-61.
30. Hajos S, Carbonetto C, Margni RA, Esteva M, Segura E. Purification and biological properties of anti-Trypanosoma cruzi antibodies isolated from patients with chronic Chagas' disease. Immunol Lett 1982; 4: 199-203.
31. Margni RA, Parma AE, Cerone S, Erpelding A, Perdigón G. Agglutinating and non-agglutinating antibodies in rabbits inoculated with a particulate antigen (Salmonella typhimurium). Immunology 1983; 48:351-9.
32. Carbonetto CH, Malchiodi EL, Margni RA. IgG antibody type in sera from patients with chronic Chagas' disease. Inmunologia 1986; 5: 18-23.
33. Abatangelo C, Calcagno M, Dokmetjian J, Margni RA. La respuesta inmune humoral en conejos inmunizados con extractos tiroideos homólogos solubles y polimerizados. Medicina (Buenos Aires) 1987; 47: 606-11.
34. Parma AE, Santisteban G, Margni RA. Analysis and in vivo assay of cattle agglutinating and non-agglutinating antibodies. Vet Microbiol 1984; 9: 391-8.
35. Gentile T, Malan Borel I, Angelucci J, Miranda S, Margni R. Preferential synthesis of asymmetric antibodies in rats immunized with paternal particulate antigen. Effect on pregnancy. J Reprod Immunology 1994; 22: 173-83 .
36. Malan Borel I, Menezes Freire S, Canellada A, Margni RA. Effect of rat placental culture supernatants on cellular and humoral immune response. Am J Reprod Immunol 1997; 38: 366-73.
37. Margni RA, Malán Borel I, Kapovic M, Angelucci J, Miranda S, Kinsky R, et al. The proportion of symmetric and asymmetric IgG antibody molecules synthesized by a cellular clone (hybridoma) can be regulated by placental culture supernatants. Cell Immunol 1992; 42: 287-95.
38. Malan Borel I, Miranda S, Menezes Freire S, Binaghi R, Margni R. Modulation of the humoral immune response by placental secretory factors. Am J Reprod Immunol 1996; 35: 529-33.
39. Miranda S, Malan Borel I, Menezez Freire S, Binaghi R, Margni RA. Influence of mouse placental factors on in vitro antibody sinthesis. J Reprod Immunol 1996; 30: 151-71.
40. Gutiérrez G, Malan Borel I, Margni RA. The placental regulatory factor involved in asymmetric IgG antibody synthesis responds to IL-6 features. J Reprod Immunol 2001; 49: 21-32.
41. Canellada A, et al. Interleukin regulation of asymmetric antibody synthesized by isolated placental B cells. Am J Reprod Immunol (In press).
42. Miranda S, Gentile T, Margni R. Enhancement of in vito Hsp synthesis by placental IL-6. Am J Reprod Immunol 2001; 46: 358-64.
43. Miranda S, Canellada A, Gentile T, Margni R. In vitro modulation of UDP-Glc glycoprotein glycosyltransferase activivity by recombinant interleukin-6. Scand J Immunol 2001; 54, 2: 18/275, 41.
44. Trombetta S, Bosch M, Parodi A. Glucosylation of glycoprotein by mammalian, plant, fungal and trypanosomatid protozoa microsomal membranes. Biochemistry 1989; 28: 8108-16.
45. Clark DA. Worldwide collaborative observational study and meta analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32: 55-72.
46. Mowbray JF, Liddel H, Underwood JL, Gibbins C, Beard RW. Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells. Lancet 1985; 1: 941-9.
47. Gatenby PA, Cameron K, Simes RJ, Adelstein S, Bennett MJ, Jansen RPS, et al. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes results of a controlled trials. Am J Reprod Immunol 1993; 29: 88-94.
48. Miranda S, Malán Borel I, Margni R. Altered modulation of the in vitro antibody synthesis by placental factors from the CBA/J and DBA/2 abortion-prone mating combination Am J Reprod Immunol 1998; 39: 151-71.
49. Chaouat G, Assal Meliani A, Martal J, Raghupathy R, Elliot J, Mosmann T, et al. IL-10 prevents naturaly ocurring fetal loss in the CBA/J x DBA/2 mating combination and local defect in IL-10 production in the abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol 1995; 154: 4261-8.
50. Zenclussen A, Gentile T, Kortebani G, Mazzolli A, Margni R. Asymmetric antibodies and pregnancy. Am J Reprod Immunol 2001; 45: 289-94.
51. Zencluseen A, Roux ME, Mazzolli A, Kortebani G, Margni R, Malán Borel I. Interleukin 6 in abortion and normal placentae hystological samples. Placenta 1999; 20 5/6 A: 73.
52. Zencluseen A, Mazzolli A, Kortebani G, Margni R, Malan Borel, I. IL-6 and sIL-6R serum levels in recurrent spontaneous abortion in women immunized with paternal white cells. Am J Reprod Immunol 2000; 44, 22-9.
53. Chaouat G. Cytokine networks at the feto maternal interface: Are the existing paradigms still valid? Am J Reprod Immunol 2001; 46: MS2-1.
54. Croy BA. Where now for the Th1/Th2 paradigm of the gestational uterus? J Reprod Immunol 2001; 51: 1-2.
55. Arck PC, Zenclussen AC, Fest S, Sehmsdorf U, Klapp B. Challenging the Th1/Th2 dichtomy. Am J Reprod Immunol 2001 45(6): P11.
56. Kelemen K, Bognar J, Paal M, Szekeres-Bartho J. A progesterone-induced protein increases the synthesis of asymmetric molecules. Cell Immunol 1996: 167: 129-34.
57. Gentile T, Margni RA. IgG asymmetric anti-ovalbumin antibodies synthesized by virgin and pregnant rats. J Reprod Immunol 1995; 28: 1-13.
58. Miranda S, Malán Borel I, Dokmetjian J, Margni R, Binaghi R. Asymmetric non-precipitating antibodies in commercial hyperimmune gammaglobulin for therapeutic use. Immunology 1992; 75: 707-9.
59. Pasetti M, Dokmetjian J, Brero ML, Eriksson P, Ferrero E, Manghi M. Structure and protective capacity of tetanus and diphtheria antibodies produced during human pregnancy and transferred to new born. Am J Reprod Immunol 1997; 37: 250-6.
60. Tao MH, Morrison SL. Studies of aglycosylated mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143: 2595-601.
61. Bond A, Alavi A, Axford J, Youinou P, Hay FC. The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis, juvenile chronic arthritis and Sjögren's syndrome. Clin Exp Immunol 1996; 105: 99-103.
62. Mullinax F, Mullinax G. Abnormality of IgG structure in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1975; 18: 417-8.
63. Tomana M, Schrohenloher R, Koopman W, Alarcon G, Paul W Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Reum 1988; 31: 333-8.
64. Grebenau RC, Goldenberg DM, Chang CH, Koch GA, Gold DV, Kunz A, et al. Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation. Mol Immunol 1992; 29: 751-8.
65. Coloma MJ, Trinh R, Martinez A, Morrison SJ. Position effects of variable region carbohydrate on the affinity an in vivo behaviour of an Anti-(1-6) dextran antibody. Immunol 1999; 162: 2162-70.
66. Co MS, Scheimberg N, Avdalovic NM, Mc Graw K, Vasquez M, Caron P, et al. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol 1993; 30: 1361-7.
67. Wright A, Tao MH, Kabat EA, Morrisson SL. Antibody variable region glycosylation: Position effects on antigen binding and carbohydrate structure. EMBO J 1991; 10: 2717-23.
68. Wallick SC, Kabat EA, Morrison SL. Glycosylation of a VII residue of a monoclonal antibody against alpha (1-6) dextran increases its affinity for antigens. J Exp Med 1988; 168: 1099-109.